Profusa reports Q2 2026 loss, advances G3 Vision Labs deal

Profusa, Inc. (Nasdaq: PFSA) reported a net loss of $8.8 million for the three months ended June 30, 2026, compared to a net loss of $2.3 million in the same period a year earlier, according to a company press release.

For the six months ended June 30, 2026, the net loss was $12.2 million, up from $5.1 million for the same period in 2025. Cash on hand at June 30, 2026 was $719,000, with total assets of $1.0 million and total liabilities of $28.2 million. The total stockholders' deficit stood at $27.1 million as of June 30, 2026.

The company said stockholders' equity as of July 31, 2026 is expected to reach $28.4 million following the execution of an Option Agreement providing Profusa the right, but not the obligation, to acquire G3 Vision Labs, Inc. and its subsidiaries.

Debt and liability holders have executed $10.7 million in Series A Convertible Exchange Agreements, of which $4.57 million was converted into 4,271 shares of Series A Convertible Preferred Stock. Profusa also borrowed $650,000 under an existing note agreement to meet near-term working capital needs.

A 4:1 reverse stock split took effect August 18, 2026, which the company said supports meeting Nasdaq minimum listing requirements. Profusa's Certificate of Designation for its Non-Voting Series A Convertible Preferred Stock is now in effect.

G3's auditors are finalizing audits of the 2024 and 2025 financial statements, with most entities expected to receive audited financials by the end of August and the full audit completed by mid-September.

G3 operates CLIA-certified national medical laboratories providing molecular diagnostic and toxicology testing, serving addiction treatment, pain management, and behavioral health providers.

"I am very pleased with the timely progress we are making and support we are receiving towards executing the Option to acquire G3," said Executive Chairman and CEO Jack Stover.

You May Also Be Interested In

• US Treasury: 'Authorizing Wind Down Activities...the Offloading of Cargo Involving Certain Persons or Vessels Blocked on October 21, 2026'
• Inovio Pharma (INO) November 0.5 calls active, share price down 18.7%
• Danaher (DHR) 3500 contracts of November 200 puts trade